NeuBase Therapeutics Announces Addition of Industry Pioneer Dr. Samuel Broder and World-Renowned Geneticist Dr. George Church to Scientific Advisory Board

NEXT STORY
Principia Announces Update to Ongoing Phase 2 Clinical Trial in Patients with ITP
PREV STORY
Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cynata Reports Positive 28-day Data From Cohort B of Phase 1 Trial of CYP-001 in GvHD

MELBOURNE, Australia, June 21, 2018 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine ...

author_avatar
NASDAQ Market News

Biocartis Group NV: Biocartis announces 2017 half-year results on 7 September 2017

PRESS RELEASE - REGULATED INFORMATION                       ...

author_avatar
NASDAQ Market News

Cyfluent Achieves EHNAC Cloud-Enabled Accreditation

CEAP accreditation offers a higher level of stakeholder confidence for organizations under competitive pressures ...

author_avatar
NASDAQ Market News